Asia Pacific Biopharmaceuticals Market Outlook, 2029

The Asia Pacific Biopharmaceuticals Market is estimated to reach a staggering USD 78.69 billion by 2029, reflecting a robust CAGR of 10.05%, driven by growing focus in generics.

According to publisher, Here is a Booming Biotech Hub Asia Pacific Biopharmaceuticals Market. The Asia Pacific biopharmaceuticals market is experiencing a period of significant growth, fueled by an aging population, rising healthcare spending, and government support for innovation. The market size is estimated to reach a staggering USD 78.69 billion by 2029, reflecting a robust CAGR of 10.05%. Here's a glimpse into this dynamic market: Market Insights

What's Inside a Bonafide Research`s industry report?

Asia-Pacific dominates the market and is the largest and fastest-growing market in the animal growth promoters industry globally

Download Sample

Aging Population: A rapidly aging population in countries like China and Japan is driving demand for biopharmaceuticals used to treat chronic diseases like diabetes and cancer. Rising Healthcare Expenditure: Economic growth across the region is leading to increased healthcare spending, allowing for greater investment in biopharmaceutical products. Market Dynamics

Make this report your own

Have queries/questions regarding a report?

Take advantage of intelligence tailored to your business objective

Manmayi Raval

Manmayi Raval

Research Consultant

Drivers: Government Initiatives: Government programs and incentives are promoting biopharmaceutical research and development (R&D) within the region. (e.g., China's national biotech strategy) Growing Focus on Generics: The increasing demand for affordable medications is driving the growth of the generics market in Asia Pacific.

Don’t pay for what you don’t need. Save 30%

Customise your report by selecting specific countries or regions

Specify Scope Now
Manmayi Raval

Restraints: Intellectual Property (IP) Concerns: Stringent patent laws and challenges in enforcing intellectual property rights can hinder innovation by domestic companies. Regulatory Hurdles: Complex and lengthy regulatory approval processes can delay the market entry of new biopharmaceuticals. Market Segments Product Type: Biologics: These drugs, derived from living organisms, are used to treat various diseases like cancer and autoimmune disorders. (e.g., monoclonal antibodies) Biosimilars: Similar to biologics but more affordable, biosimilars are gaining traction due to patent expiries on original drugs. Application: Oncology: Rising cancer rates are driving demand for innovative cancer treatments like targeted therapies and immunotherapies. Chronic Diseases: Biopharmaceuticals play a significant role in managing chronic conditions like diabetes and cardiovascular diseases. Regional Analysis China's Dominance: China is the undisputed leader in the Asia Pacific biopharmaceutical market due to its large population base, government support, and growing biopharmaceutical manufacturing capabilities. India's Potential: India is a major player in the generics market and is increasingly focusing on biosimilar development, making it a strong contender in the region. Other Emerging Markets: South Korea, Japan, and Australia are witnessing significant growth in their biopharmaceutical industries, with a focus on innovation and niche markets. Key Developments Rise of Contract Manufacturing Organizations (CMOs): CMOs provide biopharmaceutical manufacturing services to other companies, creating a more efficient and cost-effective production environment. Focus on Biosimilars: The expiration of patents on major biologics is creating opportunities for the development and market entry of biosimilars. Increasing R&D Investments: Both domestic and multinational biopharmaceutical companies are investing heavily in R&D to develop innovative treatments for diseases prevalent in the region. Competitive Landscape Mix of Global Players and Local Companies: Multinational pharmaceutical giants like Roche and Pfizer have a strong presence, but domestic companies like Biocon (India) and BeiGene (China) are making significant strides. Strategic Collaborations: Partnerships between global and local companies are accelerating innovation and market access for biopharmaceuticals. Future Outlook The Asia Pacific biopharmaceuticals market is brimming with potential, driven by: Clearer regulatory pathways Technological advancements in biomanufacturing Growing biopharmaceutical talent pool This will lead to: A wider range of biopharmaceutical products: Expect to see a greater availability of innovative drugs, biosimilars, and personalized medicine solutions. Focus on affordability: As the market matures, expect to see cost-effective biopharmaceutical solutions catering to the needs of developing countries within the region. The Asia Pacific region is poised to become a global leader in biopharmaceutical innovation and production. Its focus on affordability, domestic R&D, and strategic collaborations will be instrumental in shaping the future of biopharmaceutical development for years to come.

Table of Contents

  • 1 Introduction 9
  • 1.1 Industry Definition and Research Scope 9
  • 1.1.1 Industry Definition 9
  • 1.1.2 Research Scope 10
  • 1.2 Research Methodology 13
  • 1.2.1 Overview of Market Research Methodology 13
  • 1.2.2 Market Assumption 14
  • 1.2.3 Secondary Data 14
  • 1.2.4 Primary Data 14
  • 1.2.5 Data Filtration and Model Design 15
  • 1.2.6 Market Size/Share Estimation 16
  • 1.2.7 Research Limitations 17
  • 1.3 Executive Summary 18
  • 2 Market Overview and Dynamics 21
  • 2.1 Market Size and Forecast 21
  • 2.1.1 Impact of COVID-19 on World Economy 22
  • 2.1.2 Impact of COVID-19 on the Market 26
  • 2.1.3 Impact of Russia-Ukraine Conflict 28
  • 2.1.4 Impact of Israel-Palestine War 30
  • 2.2 Major Growth Drivers 31
  • 2.3 Market Restraints and Challenges 40
  • 2.4 Emerging Opportunities and Market Trends 43
  • 2.5 Porter’s Fiver Forces Analysis 47
  • 3 Segmentation of Asia Pacific Market by Product Type 51
  • 3.1 Market Overview by Product Type 51
  • 3.2 Monoclonal Antibodies 53
  • 3.2.1 Anti-cancer Monoclonal Antibodies 54
  • 3.2.2 Anti-inflammatory Monoclonal Antibodies 55
  • 3.2.3 Other Monoclonal Antibodies 56
  • 3.3 Recombinant Growth Factors 57
  • 3.3.1 Erythropoietin 58
  • 3.3.2 Granulocyte Colony Stimulating Factor 59
  • 3.4 Purified Proteins 60
  • 3.4.1 Leukemia Inhibitory Factor (LIF) 61
  • 3.4.2 P53 Protein 62
  • 3.4.3 P38 Protein 63
  • 3.4.4 Other Purified Proteins 64
  • 3.5 Recombinant Proteins 65
  • 3.5.1 Serum Albumin 66
  • 3.5.2 Amyloid Protein 67
  • 3.5.3 Defensin 68
  • 3.5.4 Transferrin 69
  • 3.6 Recombinant Hormones 70
  • 3.6.1 Recombinant Human Growth Hormones 71
  • 3.6.2 Recombinant Insulin 73
  • 3.6.3 Other Recombinant Hormones 74
  • 3.7 Vaccines 75
  • 3.7.1 Recombinant Vaccines 76
  • 3.7.2 Conventional Vaccines 78
  • 3.8 Recombinant Enzymes 79
  • 3.8.1 Enterokinase 80
  • 3.8.2 Cyclase 81
  • 3.8.3 Caspase 82
  • 3.8.4 Cathepsin 83
  • 3.9 Cell and Gene Therapies 84
  • 3.9.1 Allogenic Products 85
  • 3.9.2 Autologous Products 86
  • 3.9.3 Acellular Products 87
  • 3.10 Synthetic Immunomodulators 88
  • 3.11 Other Product Types 89
  • 3.11.1 Blood Factors 90
  • 3.11.2 Other Products 91
  • 4 Segmentation of Asia Pacific Market by Testing Service 92
  • 4.1 Market Overview by Testing Service 92
  • 4.2 Laboratory Testing 94
  • 4.3 Custom Testing/Customer Proprietary Testing 95
  • 4.4 Compendial and Multi Compendial Laboratory Testing 96
  • 5 Segmentation of Asia Pacific Market by Raw Material 97
  • 5.1 Market Overview by Raw Material 97
  • 5.2 Formulation Excipients 99
  • 5.3 Active Pharmaceutical Ingredients (API) 100
  • 5.4 Other Materials 101
  • 6 Segmentation of Asia Pacific Market by Classification 102
  • 6.1 Market Overview by Classification 102
  • 6.2 Innovative Biopharmaceuticals 104
  • 6.3 Biogenerics and Biosimilars 105
  • 7 Segmentation of Asia Pacific Market by Therapeutic Area 106
  • 7.1 Market Overview by Therapeutic Area 106
  • 7.2 Oncology 108
  • 7.3 Inflammatory and Infectious Diseases 109
  • 7.4 Autoimmune Disorders 110
  • 7.5 Metabolic Disorders 111
  • 7.6 Hormonal Disorders 112
  • 7.7 Cardiovascular Diseases 113
  • 7.8 Neurological Diseases 114
  • 7.9 Other Therapeutic Areas 115
  • 8 Asia-Pacific Market 2023-2033 by Country 116
  • 8.1 Overview of Asia-Pacific Market 116
  • 8.2 Japan 119
  • 8.3 China 122
  • 8.4 Australia 124
  • 8.5 India 126
  • 8.6 South Korea 128
  • 8.7 Rest of APAC Region 130
  • 9 Competitive Landscape 132
  • 9.1 Overview of Key Vendors 132
  • 9.2 New Product Launch, Partnership, Investment, and M&A 136
  • 9.3 Company Profiles 137
  • Abbott Laboratories 137
  • Amgen Inc. 139
  • Astrazeneca PLC 140
  • Bayer AG 141
  • Biogen Inc. 142
  • Bristol-myers Squibb Company (BMS) 143
  • Eli Lilly and Company 144
  • F. Hoffmann-La Roche Ltd. 145
  • Glaxosmithkline PLC 146
  • Johnson & Johnson 147
  • Merck & Co. Inc. 148
  • Novartis Ag 149
  • Novo Nordisk As 150
  • Pfizer Inc. 151
  • Sanofi Sa 152
  • Sharp Packaging Services 153
  • Sun Pharmaceutical Industries Ltd. 154
  • Takeda Pharmaceutical Company Limited 155
  • Thermo Fisher Scientific Inc. 156
  • Vertex Pharmaceuticals 157
  • WuXi AppTec 158
  • RELATED REPORTS 159



Table 1. Snapshot of Asia Pacific Biopharmaceuticals Market in Balanced Perspective, 2023-2033 19
Table 2. World Economic Outlook, 2024-2036 23
Table 3. World Economic Outlook, 2022-2024 25
Table 4. Scenarios for Economic Impact of Ukraine Crisis 29
Table 5. Scenarios for Economic Impact of Israel-Palestine War 30
Table 6. World Health Spending by Region, $ bn, 2013-2020 35
Table 7. Total Number of Registered Clinical Studies Worldwide, 2010-2021 36
Table 8. Worldwide Number of New Cancer by Type, 2020 37
Table 9. Main Product Trends and Market Opportunities in Asia Pacific Biopharmaceuticals Market 43
Table 10. Asia Pacific Biopharmaceuticals Market by Product Type, 2023-2033, $ mn 51
Table 11. Asia Pacific Biopharmaceuticals Market: Monoclonal Antibodies by Type, 2023-2033, $ mn 53
Table 12. Asia Pacific Biopharmaceuticals Market: Recombinant Growth Factor by Type, 2023-2033, $ mn 57
Table 13. Asia Pacific Biopharmaceuticals Market: Purified Proteins by Type, 2023-2033, $ mn 60
Table 14. Asia Pacific Biopharmaceuticals Market: Recombinant Proteins by Type, 2023-2033, $ mn 65
Table 15. Asia Pacific Biopharmaceuticals Market: Recombinant Hormones by Type, 2023-2033, $ mn 70
Table 16. Selected Drugs for COVID-19 Treatment in Development, Nov 2022 72
Table 17. Asia Pacific Biopharmaceuticals Market: Vaccines by Type, 2023-2033, $ mn 75
Table 18. Asia Pacific Biopharmaceuticals Market: Recombinant Vaccines by Type, 2023-2033, $ mn 77
Table 19. Asia Pacific Biopharmaceuticals Market: Conventional Vaccines by Type, 2023-2033, $ mn 78
Table 20. Asia Pacific Biopharmaceuticals Market: Recombinant Enzymes by Type, 2023-2033, $ mn 79
Table 21. Asia Pacific Biopharmaceuticals Market: Cell and Gene Therapies by Type, 2023-2033, $ mn 84
Table 22. Asia Pacific Biopharmaceuticals Market: Other Product Types by Type, 2023-2033, $ mn 89
Table 23. Asia Pacific Biopharmaceuticals Market by Testing Service, 2023-2033, $ mn 92
Table 24. Asia Pacific Biopharmaceuticals Market by Raw Material, 2023-2033, $ mn 97
Table 25. Asia Pacific Biopharmaceuticals Market by Classification, 2023-2033, $ mn 102
Table 26. Asia Pacific Biopharmaceuticals Market by Therapeutic Area, 2023-2033, $ mn 106
Table 27. APAC Biopharmaceuticals Market by Country, 2023-2033, $ mn 117
Table 28. Japan Biopharmaceuticals Market by Product Type, 2023-2033, $ mn 121
Table 29. Japan Biopharmaceuticals Market by Therapeutic Area, 2023-2033, $ mn 121
Table 30. China Biopharmaceuticals Market by Product Type, 2023-2033, $ mn 123
Table 31. China Biopharmaceuticals Market by Therapeutic Area, 2023-2033, $ mn 123
Table 32. Australia Biopharmaceuticals Market by Product Type, 2023-2033, $ mn 125
Table 33. Australia Biopharmaceuticals Market by Therapeutic Area, 2023-2033, $ mn 125
Table 34. India Biopharmaceuticals Market by Product Type, 2023-2033, $ mn 127
Table 35. India Biopharmaceuticals Market by Therapeutic Area, 2023-2033, $ mn 127
Table 36. South Korea Biopharmaceuticals Market by Product Type, 2023-2033, $ mn 129
Table 37. South Korea Biopharmaceuticals Market by Therapeutic Area, 2023-2033, $ mn 129
Table 38. Biopharmaceuticals Market in Rest of APAC by Country/Region, 2023-2033, $ mn 131
Table 39. Abbott Laboratories: Company Snapshot 137
Table 40. Abbott Laboratories: Business Segmentation 138
Table 41. Abbott Laboratories: Product Portfolio 138



Figure 1. Research Method Flow Chart 13
Figure 2. Bottom-up Approach and Top-down Approach for Market Estimation 16
Figure 3. Asia Pacific Market Forecast in Optimistic, Conservative and Balanced Perspectives, 2023-2033 18
Figure 4. Asia Pacific Biopharmaceuticals Market, 2023-2033, $ mn 21
Figure 5. Impact of COVID-19 on Business 26
Figure 6. Primary Drivers and Impact Factors of Asia Pacific Biopharmaceuticals Market 31
Figure 7. Worldwide Geriatric Population (60 years and above) by Regions, 2015 & 2030, million 34
Figure 8. World Population 65 and Over, % of Total Population, 1950-2060 34
Figure 9. Worldwide Novel Active Substances (NASs) Launches by Therapeutic Area, 2013-2022 35
Figure 10. Primary Restraints and Impact Factors of Asia Pacific Biopharmaceuticals Market 40
Figure 11. Investment Opportunity Analysis 44
Figure 12. Porter’s Fiver Forces Analysis of Asia Pacific Biopharmaceuticals Market 47
Figure 13. Breakdown of Asia Pacific Biopharmaceuticals Market by Product Type, 2023-2033, % of Revenue 52
Figure 14. Asia Pacific Addressable Market Cap in 2024-2033 by Product Type, Value ($ mn) and Share (%) 52
Figure 15. Asia Pacific Biopharmaceuticals Market by Product Type: Monoclonal Antibodies, 2023-2033, $ mn 53
Figure 16. Asia Pacific Biopharmaceuticals Market by Monoclonal Antibodies: Anti-cancer Monoclonal Antibodies, 2023-2033, $ mn 54
Figure 17. Asia Pacific Biopharmaceuticals Market by Monoclonal Antibodies: Anti-inflammatory Monoclonal Antibodies, 2023-2033, $ mn 55
Figure 18. Asia Pacific Biopharmaceuticals Market by Monoclonal Antibodies: Other Monoclonal Antibodies, 2023-2033, $ mn 56
Figure 19. Asia Pacific Biopharmaceuticals Market by Product Type: Recombinant Growth Factors, 2023-2033, $ mn 57
Figure 20. Asia Pacific Biopharmaceuticals Market by Recombinant Growth Factor: Erythropoietin, 2023-2033, $ mn 58
Figure 21. Asia Pacific Biopharmaceuticals Market by Recombinant Growth Factor: Granulocyte Colony Stimulating Factor, 2023-2033, $ mn 59
Figure 22. Asia Pacific Biopharmaceuticals Market by Product Type: Purified Proteins, 2023-2033, $ mn 60
Figure 23. Asia Pacific Biopharmaceuticals Market by Purified Proteins: Leukemia Inhibitory Factor (LIF), 2023-2033, $ mn 61
Figure 24. Asia Pacific Biopharmaceuticals Market by Purified Proteins: P53 Protein, 2023-2033, $ mn 62
Figure 25. Asia Pacific Biopharmaceuticals Market by Purified Proteins: P38 Protein, 2023-2033, $ mn 63
Figure 26. Asia Pacific Biopharmaceuticals Market by Purified Proteins: Other Purified Proteins, 2023-2033, $ mn 64
Figure 27. Asia Pacific Biopharmaceuticals Market by Product Type: Recombinant Proteins, 2023-2033, $ mn 65
Figure 28. Asia Pacific Biopharmaceuticals Market by Recombinant Proteins: Serum Albumin, 2023-2033, $ mn 66
Figure 29. Asia Pacific Biopharmaceuticals Market by Recombinant Proteins: Amyloid Protein, 2023-2033, $ mn 67
Figure 30. Asia Pacific Biopharmaceuticals Market by Recombinant Proteins: Defensin, 2023-2033, $ mn 68
Figure 31. Asia Pacific Biopharmaceuticals Market by Recombinant Proteins: Transferrin, 2023-2033, $ mn 69
Figure 32. Asia Pacific Biopharmaceuticals Market by Product Type: Recombinant Hormones, 2023-2033, $ mn 70
Figure 33. Asia Pacific Biopharmaceuticals Market by Recombinant Hormones: Recombinant Human Growth Hormones, 2023-2033, $ mn 71
Figure 34. Asia Pacific Biopharmaceuticals Market by Recombinant Hormones: Recombinant Insulin, 2023-2033, $ mn 73
Figure 35. Asia Pacific Biopharmaceuticals Market by Recombinant Hormones: Other Recombinant Hormones, 2023-2033, $ mn 74
Figure 36. Asia Pacific Biopharmaceuticals Market by Product Type: Vaccines, 2023-2033, $ mn 75
Figure 37. Asia Pacific Biopharmaceuticals Market by Vaccines: Recombinant Vaccines, 2023-2033, $ mn 76
Figure 38. Asia Pacific Biopharmaceuticals Market by Vaccines: Conventional Vaccines, 2023-2033, $ mn 78
Figure 39. Asia Pacific Biopharmaceuticals Market by Product Type: Recombinant Enzymes, 2023-2033, $ mn 79
Figure 40. Asia Pacific Biopharmaceuticals Market by Recombinant Enzymes: Enterokinase, 2023-2033, $ mn 80
Figure 41. Asia Pacific Biopharmaceuticals Market by Recombinant Enzymes: Cyclase, 2023-2033, $ mn 81
Figure 42. Asia Pacific Biopharmaceuticals Market by Recombinant Enzymes: Caspase, 2023-2033, $ mn 82
Figure 43. Asia Pacific Biopharmaceuticals Market by Recombinant Enzymes: Cathepsin, 2023-2033, $ mn 83
Figure 44. Asia Pacific Biopharmaceuticals Market by Product Type: Cell and Gene Therapies, 2023-2033, $ mn 84
Figure 45. Asia Pacific Biopharmaceuticals Market by Cell and Gene Therapies: Allogenic Products, 2023-2033, $ mn 85
Figure 46. Asia Pacific Biopharmaceuticals Market by Cell and Gene Therapies: Autologous Products, 2023-2033, $ mn 86
Figure 47. Asia Pacific Biopharmaceuticals Market by Cell and Gene Therapies: Acellular Products, 2023-2033, $ mn 87
Figure 48. Asia Pacific Biopharmaceuticals Market by Product Type: Synthetic Immunomodulators, 2023-2033, $ mn 88
Figure 49. Asia Pacific Biopharmaceuticals Market by Product Type: Other Product Types, 2023-2033, $ mn 89
Figure 50. Asia Pacific Biopharmaceuticals Market by Other Product Types: Blood Factors, 2023-2033, $ mn 90
Figure 51. Asia Pacific Biopharmaceuticals Market by Other Product Types: Other Products, 2023-2033, $ mn 91
Figure 52. Breakdown of Asia Pacific Biopharmaceuticals Market by Testing Service, 2023-2033, % of Sales Revenue 93
Figure 53. Asia Pacific Addressable Market Cap in 2024-2033 by Testing Service, Value ($ mn) and Share (%) 93
Figure 54. Asia Pacific Biopharmaceuticals Market by Testing Service: Laboratory Testing, 2023-2033, $ mn 94
Figure 55. Asia Pacific Biopharmaceuticals Market by Testing Service: Custom Testing/Customer Proprietary Testing, 2023-2033, $ mn 95
Figure 56. Asia Pacific Biopharmaceuticals Market by Testing Service: Compendial and Multi Compendial Laboratory Testing, 2023-2033, $ mn 96
Figure 57. Breakdown of Asia Pacific Biopharmaceuticals Market by Raw Material, 2023-2033, % of Sales Revenue 98
Figure 58. Asia Pacific Addressable Market Cap in 2024-2033 by Raw Material, Value ($ mn) and Share (%) 98
Figure 59. Asia Pacific Biopharmaceuticals Market by Raw Material: Formulation Excipients, 2023-2033, $ mn 99
Figure 60. Asia Pacific Biopharmaceuticals Market by Raw Material: Active Pharmaceutical Ingredients (API), 2023-2033, $ mn 100
Figure 61. Asia Pacific Biopharmaceuticals Market by Raw Material: Other Materials, 2023-2033, $ mn 101
Figure 62. Breakdown of Asia Pacific Biopharmaceuticals Market by Classification, 2023-2033, % of Revenue 103
Figure 63. Asia Pacific Addressable Market Cap in 2024-2033 by Classification, Value ($ mn) and Share (%) 103
Figure 64. Asia Pacific Biopharmaceuticals Market by Classification: Innovative Biopharmaceuticals, 2023-2033, $ mn 104
Figure 65. Asia Pacific Biopharmaceuticals Market by Classification: Biogenerics and Biosimilars, 2023-2033, $ mn 105
Figure 66. Breakdown of Asia Pacific Biopharmaceuticals Market by Therapeutic Area, 2023-2033, % of Revenue 107
Figure 67. Asia Pacific Addressable Market Cap in 2024-2033 by Therapeutic Area, Value ($ mn) and Share (%) 107
Figure 68. Asia Pacific Biopharmaceuticals Market by Therapeutic Area: Oncology, 2023-2033, $ mn 108
Figure 69. Asia Pacific Biopharmaceuticals Market by Therapeutic Area: Inflammatory and Infectious Diseases, 2023-2033, $ mn 109
Figure 70. Asia Pacific Biopharmaceuticals Market by Therapeutic Area: Autoimmune Disorders, 2023-2033, $ mn 110
Figure 71. Asia Pacific Biopharmaceuticals Market by Therapeutic Area: Metabolic Disorders, 2023-2033, $ mn 111
Figure 72. Asia Pacific Biopharmaceuticals Market by Therapeutic Area: Hormonal Disorders, 2023-2033, $ mn 112
Figure 73. Asia Pacific Biopharmaceuticals Market by Therapeutic Area: Cardiovascular Diseases, 2023-2033, $ mn 113
Figure 74. Asia Pacific Biopharmaceuticals Market by Therapeutic Area: Neurological Diseases, 2023-2033, $ mn 114
Figure 75. Asia Pacific Biopharmaceuticals Market by Therapeutic Area: Other Therapeutic Areas, 2023-2033, $ mn 115
Figure 76. Breakdown of APAC Biopharmaceuticals Market by Country, 2023 and 2033, % of Revenue 117
Figure 77. Contribution to APAC 2024-2033 Cumulative Market by Country, Value ($ mn) and Share (%) 118
Figure 78. Biopharmaceuticals Market in Japan, 2023-2033, $ mn 120
Figure 79. Biopharmaceuticals Market in China, 2023-2033, $ mn 122
Figure 80. Biopharmaceuticals Market in Australia, 2023-2033, $ mn 124
Figure 81. Biopharmaceuticals Market in India, 2023-2033, $ mn 126
Figure 82. Biopharmaceuticals Market in South Korea, 2023-2033, $ mn 128
Figure 83. Biopharmaceuticals Market in Rest of APAC, 2023-2033, $ mn 130
Figure 84. Growth Stage of Asia Pacific Biopharmaceuticals Industry over the Forecast Period 132
Figure 85. Worldwide Top Ten Best-selling Biotech Drugs in 2022, $ bn 134
Logo

Asia Pacific Biopharmaceuticals Market Outlook, 2029

Contact usWe are friendly and approachable, give us a call.